ATE420873T1 - Chemokin rezeptor bindenden heterozyklische verbindungen - Google Patents
Chemokin rezeptor bindenden heterozyklische verbindungenInfo
- Publication number
- ATE420873T1 ATE420873T1 AT01973887T AT01973887T ATE420873T1 AT E420873 T1 ATE420873 T1 AT E420873T1 AT 01973887 T AT01973887 T AT 01973887T AT 01973887 T AT01973887 T AT 01973887T AT E420873 T1 ATE420873 T1 AT E420873T1
- Authority
- AT
- Austria
- Prior art keywords
- chemokine receptor
- receptor binding
- heterocyclic compounds
- binding heterocyclic
- multiplicity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23308700P | 2000-09-15 | 2000-09-15 | |
US23481600P | 2000-09-22 | 2000-09-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE420873T1 true ATE420873T1 (de) | 2009-01-15 |
Family
ID=26926617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01973887T ATE420873T1 (de) | 2000-09-15 | 2001-09-17 | Chemokin rezeptor bindenden heterozyklische verbindungen |
Country Status (18)
Country | Link |
---|---|
US (3) | US6835731B2 (de) |
EP (1) | EP1317443B1 (de) |
JP (1) | JP2004508421A (de) |
KR (1) | KR20030029997A (de) |
CN (1) | CN1237061C (de) |
AT (1) | ATE420873T1 (de) |
AU (2) | AU9355101A (de) |
BR (1) | BR0113931A (de) |
CA (1) | CA2419219A1 (de) |
DE (1) | DE60137435D1 (de) |
HU (1) | HUP0301094A2 (de) |
IL (1) | IL154228A0 (de) |
MX (1) | MXPA03002325A (de) |
NO (1) | NO20031178D0 (de) |
NZ (1) | NZ524421A (de) |
PL (1) | PL360141A1 (de) |
SG (1) | SG126006A1 (de) |
WO (1) | WO2002022599A2 (de) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6835731B2 (en) * | 2000-09-15 | 2004-12-28 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
ATE335733T1 (de) | 2000-09-15 | 2006-09-15 | Anormed Inc | Chemokin rezeptor bindenden heterozyklischen verbindungen |
IL154227A0 (en) | 2000-09-15 | 2003-07-31 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
US7141590B2 (en) | 2000-12-29 | 2006-11-28 | Ucb Sa | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides |
GB0108099D0 (en) * | 2001-03-30 | 2001-05-23 | Hoffmann La Roche | Aminopiperidine derivatives |
AU2002318927B2 (en) | 2001-07-31 | 2007-01-04 | Genzyme Corporation | Methods to mobilize progenitor/stem cells |
US7169750B2 (en) | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
KR20040068339A (ko) * | 2001-12-21 | 2004-07-30 | 아노르메드 인코포레이티드 | 효능이 강화된 케모카인 수용체 결합 헤테로사이클릭 화합물 |
US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
RU2005102004A (ru) | 2002-06-27 | 2005-10-20 | Шеринг Акциенгезельшафт (De) | Замещенные хинолины как антагонисты рецептора ccr5 |
US7759336B2 (en) | 2002-12-10 | 2010-07-20 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
US7291631B2 (en) | 2003-04-11 | 2007-11-06 | Genzyme Corporation | CXCR4 chemokine receptor binding compounds |
WO2004093817A2 (en) | 2003-04-22 | 2004-11-04 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US7501518B2 (en) | 2003-04-22 | 2009-03-10 | Genzyme Corporation | Methods of making 2,6-diaryl piperidine derivatives |
JP4795022B2 (ja) * | 2003-09-30 | 2011-10-19 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環化合物を含有する新規な抗真菌剤 |
US20100247540A1 (en) * | 2003-10-30 | 2010-09-30 | Chemocentryx, Inc. | Methods and Compositions For Modulating Angiogenesis |
US7498346B2 (en) | 2003-12-11 | 2009-03-03 | Genzyme Corporation | Chemokine receptor binding compounds |
WO2005059107A2 (en) | 2003-12-11 | 2005-06-30 | Anormed Inc. | Chemokine receptor binding compounds |
CA2554880A1 (en) * | 2004-02-03 | 2005-08-18 | Chemocentryx, Inc. | Methods and compositions for modulating angiogenesis |
TW200612935A (en) * | 2004-08-02 | 2006-05-01 | Smithkline Beecham Corp | Chemical compounds |
US20090227799A1 (en) * | 2004-08-09 | 2009-09-10 | Kazutaka Nakamoto | Novel Antimalarial Agent Containing Heterocyclic Compound |
AU2005272653A1 (en) * | 2004-08-13 | 2006-02-23 | Anormed Inc. | Chemokine combinations to mobilize progenitor/stem cells |
AU2005277638A1 (en) * | 2004-08-16 | 2006-03-02 | Smithkline Beecham Corporation | Chemical compounds |
WO2006022454A1 (ja) | 2004-08-27 | 2006-03-02 | Ono Pharmaceutical Co., Ltd | 塩基性基を含有する化合物およびその用途 |
WO2006026703A2 (en) * | 2004-09-02 | 2006-03-09 | Smithkline Beecham Corporation | Chemical compounds |
SI1809622T1 (sl) | 2004-09-22 | 2010-11-30 | Janssen Pharmaceutica Nv | Inhibitorji interakcije med MDM in P |
EP1793825A4 (de) * | 2004-09-24 | 2009-12-09 | Smithkline Beecham Corp | Chemische verbindungen |
TW200619206A (en) * | 2004-09-29 | 2006-06-16 | Anormed Inc | Chemokine-binding heterocyclic compound salts, and methods of use thereof |
EP1838312A4 (de) * | 2004-12-17 | 2010-01-20 | Smithkline Beecham Corp | Chemische verbindungen |
AP2007004095A0 (en) * | 2005-01-07 | 2007-08-31 | Univ Emory | Cxcr4 antagonists for the treatment of hiv infection |
JPWO2006083012A1 (ja) * | 2005-02-02 | 2008-06-26 | 味の素株式会社 | ピリミジン化合物の製造方法 |
US8680092B2 (en) | 2005-02-25 | 2014-03-25 | Ono Pharmaceutical Co., Ltd. | Nitrogenous heterocyclic compound and medicinal use thereof |
JP4874958B2 (ja) * | 2005-03-30 | 2012-02-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピリジン誘導体を含有する抗真菌剤 |
US7825088B2 (en) * | 2005-04-25 | 2010-11-02 | The Cbr Institute For Biomedical Research, Inc. | Methods for the treatment of multiple myeloma |
US8569280B2 (en) * | 2005-04-25 | 2013-10-29 | Immune Disease Institute | Methods for the treatment of multiple myeloma |
EP1898943B1 (de) * | 2005-05-25 | 2012-10-10 | Hadasit Medical Research Services & Development Ltd. | Cxcr4-antagonisten für wundheilung und reepithelialisierung |
JP2008543858A (ja) | 2005-06-15 | 2008-12-04 | ジェンザイム・コーポレーション | ケモカインレセプター結合化合物 |
EP1904501A2 (de) * | 2005-07-11 | 2008-04-02 | Smithkline Beecham Corporation | Chemische verbindungen |
AU2006280945A1 (en) | 2005-08-19 | 2007-02-22 | Genzyme Corporation | Methods to enhance chemotherapy |
TWI385169B (zh) * | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
PL1961744T3 (pl) * | 2005-11-18 | 2013-09-30 | Ono Pharmaceutical Co | Związek zawierający grupę zasadową oraz jego zastosowanie |
JP2009524689A (ja) * | 2006-01-25 | 2009-07-02 | スミスクライン ビーチャム コーポレーション | 化合物 |
EP1984376A4 (de) * | 2006-01-25 | 2009-04-08 | Smithkline Beecham Corp | Chemische verbindungen |
EP2397148A3 (de) | 2006-02-02 | 2012-04-25 | Allergan, Inc. | Zusammensetzungen und Verfahren zur Behandlung von Augenerkrankungen |
CA2644643C (en) | 2006-03-22 | 2015-05-19 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
ATE470665T1 (de) | 2006-03-22 | 2010-06-15 | Janssen Pharmaceutica Nv | Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53 |
JP5257068B2 (ja) | 2006-05-16 | 2013-08-07 | 小野薬品工業株式会社 | 保護されていてもよい酸性基を含有する化合物およびその用途 |
US20100003224A1 (en) * | 2006-08-02 | 2010-01-07 | Genzyme Corporation | Combination Therapy |
US8183264B2 (en) * | 2006-09-21 | 2012-05-22 | Eisai R&D Managment Co., Ltd. | Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same |
US8034921B2 (en) | 2006-11-21 | 2011-10-11 | Alnylam Pharmaceuticals, Inc. | IRNA agents targeting CCR5 expressing cells and uses thereof |
WO2008112164A2 (en) | 2007-03-08 | 2008-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
CN102702185A (zh) * | 2007-04-27 | 2012-10-03 | 卫材R&D管理有限公司 | 杂环取代吡啶衍生物的盐的结晶 |
TW200841879A (en) | 2007-04-27 | 2008-11-01 | Eisai R&D Man Co Ltd | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same |
EP2185541B1 (de) | 2007-08-06 | 2015-01-28 | Janssen Pharmaceutica, N.V. | Substituierte Phenylendiamine als Inhibitoren der Interaktion zwischen MDM2 und p53 |
US8513287B2 (en) * | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
BRPI0909375A2 (pt) | 2008-03-28 | 2015-08-04 | Altiris Therapeutics | Moduladores de receptores de quimiocinas |
JP2012502048A (ja) | 2008-09-08 | 2012-01-26 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法 |
US8188119B2 (en) * | 2008-10-24 | 2012-05-29 | Eisai R&D Management Co., Ltd | Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same |
KR20110082180A (ko) | 2008-10-28 | 2011-07-18 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 알데히드 탈수소효소의 조절자 및 그것의 사용방법 |
EP2393801B1 (de) | 2009-02-04 | 2017-07-12 | Janssen Pharmaceutica N.V. | Inhibitoren der interaktion zwischen mdm2 und p53 |
JP2012176900A (ja) * | 2009-06-24 | 2012-09-13 | Eisai R & D Management Co Ltd | ((ホスホノオキシ)メチル)ピリジニウム環を有するピリジン誘導体およびそれらを含有する抗真菌剤 |
ES2547072T3 (es) * | 2009-07-21 | 2015-10-01 | The Board Of Trustees Of The Leland Stanford Junior University | Heteroaril benzamidas, composiciones y métodos de utilización |
PL2509619T3 (pl) | 2009-12-11 | 2021-06-14 | Medregen, Llc | Sposoby leczenia z zastosowaniem środków do mobilizacji komórek macierzystych i środków immunosupresyjnych |
US20140219952A1 (en) | 2010-03-23 | 2014-08-07 | The Johns Hopkins University | Methods of treatment using stem cell mobilizers |
GB201005511D0 (en) * | 2010-03-31 | 2010-05-19 | Takeda Pharmaceutical | Compounds and their use |
WO2012051117A2 (en) | 2010-10-11 | 2012-04-19 | The Board Of Trustees Of The Leland Stanford Junior University | Substituted benzamides and their uses |
US9079859B2 (en) | 2011-01-21 | 2015-07-14 | Auckland Uniservices Limited | Synthetic lethal targeting of glucose transport |
CN102675305B (zh) * | 2011-03-08 | 2014-11-12 | 中国科学院上海药物研究所 | 一类咪唑并吡啶类化合物及其制备方法和用途 |
WO2012149106A1 (en) | 2011-04-29 | 2012-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
MX2014012294A (es) * | 2012-04-12 | 2015-06-05 | Ruga Corp | Benzamidas sustituidas y sus usos. |
US9316666B2 (en) | 2012-11-27 | 2016-04-19 | Murata Manufacturing Co., Ltd. | Acceleration sensor having a capacitor array located in the center of an inertial mass |
JP6410790B2 (ja) | 2013-03-14 | 2018-10-24 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ミトコンドリアアルデヒドデヒドロゲナーゼ−2調節因子およびその使用方法 |
DK3030232T3 (da) | 2013-04-29 | 2022-10-10 | Medregen Llc | Sårheling via autolog stamecellemobilisering |
AU2016269839B2 (en) | 2015-06-03 | 2021-07-08 | The University Of Queensland | Mobilizing agents and uses therefor |
CN108290878B (zh) | 2015-10-23 | 2022-04-26 | 威佛(国际)股份公司 | 新的膜铁转运蛋白抑制剂 |
CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
WO2017106332A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
US10610527B2 (en) | 2015-12-22 | 2020-04-07 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
JP2019510785A (ja) | 2016-04-08 | 2019-04-18 | エックス4 ファーマシューティカルズ, インコーポレイテッド | 癌を処置する方法 |
CA3027495A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
CA3027500A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
JP7054529B2 (ja) | 2016-06-21 | 2022-04-14 | エックス4 ファーマシューティカルズ, インコーポレイテッド | Cxcr4阻害剤およびその使用 |
WO2018073248A1 (en) | 2016-10-17 | 2018-04-26 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Prognosis of demyelinating diseases patients and treatment thereof |
JOP20180036A1 (ar) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
CA3127613A1 (en) | 2019-01-23 | 2020-07-30 | The Johns Hopkins University | Non-immunosuppressive fk506 analogs and use thereof |
CN113412261A (zh) * | 2019-04-08 | 2021-09-17 | 四川科伦博泰生物医药股份有限公司 | 苯并咪唑化合物、其制备方法及其用途 |
WO2020254872A2 (en) | 2019-06-17 | 2020-12-24 | Crispr Therapeutics Ag | Methods and compositions for improved homology directed repair |
AU2020311297A1 (en) * | 2019-07-10 | 2022-02-03 | Aucentra Therapeutics Pty Ltd | DERIVATIVES OF 4-(IMIDAZO[l,2-a]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS |
US20220228142A1 (en) | 2020-12-17 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6001826A (en) * | 1989-12-21 | 1999-12-14 | Anormed, Inc. | Chemical compounds |
GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
GB9400411D0 (en) | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
US6506770B1 (en) * | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
US6207671B1 (en) * | 1996-07-08 | 2001-03-27 | Bayer Aktiengesellschaft | Cycloalkano-pyridines |
BR9813691A (pt) * | 1997-12-19 | 2000-10-10 | Takeda Chemical Industries Ltd | Composição farmacêutica para antagonizar o ccr5, uso do composto ou um sal deste em combinação com um inibidor de protease e/ou um inibidor da transcriptase reversa, e, processo para antagonizar o ccr5. |
JP2002501898A (ja) | 1998-02-02 | 2002-01-22 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体活性の環状アミン調節剤 |
JPH11269146A (ja) | 1998-03-24 | 1999-10-05 | Mitsui Chem Inc | 分化誘導剤 |
WO1999048492A1 (fr) * | 1998-03-26 | 1999-09-30 | Japan Tobacco Inc. | Derives d'amide et antagonistes de nociceptine |
SE512225C2 (sv) | 1998-06-26 | 2000-02-14 | Jouko Haverinen | Fixtur |
AU3215500A (en) * | 1999-01-25 | 2000-08-07 | Smithkline Beecham Corporation | Compounds and methods |
US6365583B1 (en) * | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
US6362201B1 (en) | 1999-03-02 | 2002-03-26 | Merck & Co., Inc. | 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity |
HUP0200761A3 (en) * | 1999-03-24 | 2003-05-28 | Anormed Inc Langley | Chemokine receptor binding heterocyclic compounds, pharmaceutical compositions containing them and their use |
ATE335733T1 (de) * | 2000-09-15 | 2006-09-15 | Anormed Inc | Chemokin rezeptor bindenden heterozyklischen verbindungen |
IL154227A0 (en) * | 2000-09-15 | 2003-07-31 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
US6835731B2 (en) * | 2000-09-15 | 2004-12-28 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
-
2001
- 2001-09-17 US US09/957,654 patent/US6835731B2/en not_active Expired - Fee Related
- 2001-09-17 CN CNB018158013A patent/CN1237061C/zh not_active Expired - Fee Related
- 2001-09-17 BR BR0113931-2A patent/BR0113931A/pt not_active IP Right Cessation
- 2001-09-17 DE DE60137435T patent/DE60137435D1/de not_active Expired - Lifetime
- 2001-09-17 AT AT01973887T patent/ATE420873T1/de not_active IP Right Cessation
- 2001-09-17 JP JP2002526852A patent/JP2004508421A/ja active Pending
- 2001-09-17 IL IL15422801A patent/IL154228A0/xx unknown
- 2001-09-17 AU AU9355101A patent/AU9355101A/xx active Pending
- 2001-09-17 HU HU0301094A patent/HUP0301094A2/hu unknown
- 2001-09-17 MX MXPA03002325A patent/MXPA03002325A/es not_active Application Discontinuation
- 2001-09-17 AU AU2001293551A patent/AU2001293551B2/en not_active Ceased
- 2001-09-17 EP EP01973887A patent/EP1317443B1/de not_active Expired - Lifetime
- 2001-09-17 SG SG200502183A patent/SG126006A1/en unknown
- 2001-09-17 WO PCT/CA2001/001325 patent/WO2002022599A2/en active IP Right Grant
- 2001-09-17 KR KR10-2003-7003693A patent/KR20030029997A/ko not_active Application Discontinuation
- 2001-09-17 CA CA002419219A patent/CA2419219A1/en not_active Abandoned
- 2001-09-17 PL PL36014101A patent/PL360141A1/xx unknown
- 2001-09-17 NZ NZ524421A patent/NZ524421A/en unknown
-
2003
- 2003-03-14 NO NO20031178A patent/NO20031178D0/no not_active Application Discontinuation
-
2004
- 2004-08-09 US US10/914,663 patent/US7312234B2/en not_active Expired - Fee Related
-
2007
- 2007-12-13 US US11/956,190 patent/US20080090846A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PL360141A1 (en) | 2004-09-06 |
AU9355101A (en) | 2002-03-26 |
CN1237061C (zh) | 2006-01-18 |
CA2419219A1 (en) | 2002-03-21 |
SG126006A1 (en) | 2006-10-30 |
KR20030029997A (ko) | 2003-04-16 |
US20080090846A1 (en) | 2008-04-17 |
US6835731B2 (en) | 2004-12-28 |
WO2002022599A2 (en) | 2002-03-21 |
DE60137435D1 (de) | 2009-03-05 |
NZ524421A (en) | 2005-02-25 |
AU2001293551B2 (en) | 2007-08-23 |
JP2004508421A (ja) | 2004-03-18 |
US7312234B2 (en) | 2007-12-25 |
NO20031178L (no) | 2003-03-14 |
US20050026942A1 (en) | 2005-02-03 |
US20020147192A1 (en) | 2002-10-10 |
AU2001293551B8 (en) | 2002-03-26 |
HUP0301094A2 (hu) | 2003-09-29 |
WO2002022599A3 (en) | 2002-05-30 |
IL154228A0 (en) | 2003-07-31 |
EP1317443A2 (de) | 2003-06-11 |
EP1317443B1 (de) | 2009-01-14 |
NO20031178D0 (no) | 2003-03-14 |
CN1458929A (zh) | 2003-11-26 |
BR0113931A (pt) | 2004-01-13 |
MXPA03002325A (es) | 2003-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE420873T1 (de) | Chemokin rezeptor bindenden heterozyklische verbindungen | |
ATE327988T1 (de) | Chemokine rezeptor bindende heterozyklische verbindungen | |
ATE338461T1 (de) | Pyrazolpyrimidinfungizide | |
WO2004069793A3 (en) | Novel 2-substituted cyclic amines as calcium sensing receptor modulators | |
MXPA05011597A (es) | Derivados de aminopropanol como moduladores del receptor 1-fosfato de esfingosina. | |
DE60137944D1 (de) | Chemokin rezeptor bindenden heterozyklische verbindungen | |
SE9904652D0 (sv) | Novel Compounds | |
DE60143457D1 (de) | Chemokin Rezeptor bindende heterozyklische Verbindungen | |
DK2264172T3 (da) | Oligomerforbindelser til modulering af HIF-1á-ekspression | |
DK1599478T3 (da) | Dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel | |
SG155941A1 (en) | Inhibitors of the interaction between mdm2 and p53 | |
YU75601A (sh) | Postupak za pripremanje modulatora nesteroidnih glukokortikoidnih receptora | |
MXPA03008754A (es) | Derivados de piridina fundidos para utilizarse como agonistas receptores vaniloide para tratar dolor. | |
DK1337518T3 (da) | Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren | |
DK1303478T3 (da) | Fremgangsmåde til fremstilling af substituerede octanoylamider | |
ATE326454T1 (de) | Neue bernsteinsäure derivative als cysteine- protease-inhibitoren | |
ATE407122T1 (de) | Azadecalinmodulatoren des glucocorticoidrezeptors | |
DE60136667D1 (de) | Präzisionsträgerplatte | |
NO20021409D0 (no) | Hastighets-kontrollerte partikler | |
DK1206452T3 (da) | Fremgangsmåde til fremstilling af benzoperhydro-isoindolforbindelser | |
DK1347984T3 (da) | Fremgangsmåde til fremstilling af taxanderivater | |
EA200600608A1 (ru) | Производные имидазопиридина как ингибиторы индуцируемой no-синтазы | |
DK1280752T3 (da) | Fremgangsmåde til fremstilling af 2-alkyl-3-chlorphenoler | |
ATE343390T1 (de) | Kalzilytische verbindungen | |
NO20024679D0 (no) | Krystallinsk farmasöytikum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |